Exin Therapeutics
Winter 2025AI drug discovery platform for neurotherapeutics
About Company
We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL. In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding.
Active Founders
Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.
Experience in interdisciplinary research spanning Physics, Engineering and Neuroscience. DPhil in Physiology, Anatomy, and Genetics, focusing on molecular to systems level brain development and function, complemented by computational biophysical modeling.
Cofounder & COO @ Exin Therapeutics. Worked across analysis levels in bio – from molecules to complex behavior. Previously, I worked on retinal and circadian rhythm disorders, neurodevelopment, and systems and comp neuro, with a small stint in venture. Oxford MSc + PhD (on leave to build Exin).